Monitoring Report: GLP-1 RA Prescribing Trends – September 2025 Data

Samuel Gratzl, PhD*

Brianna M Goodwin Cartwright, MS*

Karen Gilbert, PhD

Duy Do, PhD

Nina Masters, MPH, PhD

Nicholas L Stucky, MD, PhD

*Denotes co-first author

Affiliations: All authors are affiliated with Truveta, Inc.

Corresponding author:
Brianna Cartwright
Truveta, Inc
1745 114th Ave SE, Bellevue, WA 98004
Email: briannac@truveta.com

Abstract

Background: Limited recent data exist on prescribing patterns and patient characteristics for glucagon-like peptide 1 receptor agonists (GLP-1 RAs), an important drug class used as anti-diabetic medication (ADM) for patients with type 2 diabetes mellitus (T2D) and/or anti-obesity medication (AOM) in patients with overweight or obesity.

For brevity, we use the term GLP-1 RA to refer to both GLP-1 RA and dual GLP-1 RA/GIP medications.

Objective: To describe recent trends in prescribing and dispensing of GLP-1-based medications in the US.

Methods: Using a subset of real-world electronic health record (EHR) data from Truveta, a growing collective of health systems that provide more than 18% of all daily clinical care in the US, we identified people who were prescribed a GLP-1-based medication between January 01, 2018 and September 30, 2025. We describe prescribing volumes and patient characteristics over time, by medication, and by FDA-labeled use. Among the subset of patients for whom post-prescription dispensing data is available, we describe the proportion and characteristics of patients who were and were not dispensed a GLP-1 RA following their prescription.

Results: 2,454,615 patients were prescribed a GLP-1 RA between January 2018 and September 2025, with 12,203,009 total prescriptions during this period. Among first-time prescriptions for which use could be established, ADMs accounted for 71.8% and AOMs accounted for 28.2%. Over the whole study period semaglutide was the most common first-time medication (n = 1,298,442), however in September 2025 tirzepatide is the most commonly prescribed first-time medication. Among those with available data, 70.2% of first-time ADM prescriptions overall and 72.2% in June 2025 had a fill within 60 days. By comparison, 46.5% of first-time AOM prescriptions overall and 46.8% in June 2025 had a fill within 60 days.

Trends in Prescribing







	GLP-1 RA	Semaglutide	Tirzepatide	Liraglutide	Dulaglutide	Other
Overall						
June 2025	6.22%	2.59%	3.28%	0.06%	0.39%	0.02%
September 2025	6.50%	2.64%	3.56%	0.07%	0.37%	0.02%
Change (percentage)	+4.60%	+2.01%	+8.36%	+17.02%	-5.64%	-24.68%
Difference (percentage points)	+0.29%	+0.05%	+0.27%	+0.01%	-0.02%	-0.01%
ADM						
June 2025	2.97%	1.20%	1.40%	0.00%	0.39%	0.02%
September 2025	3.13%	1.17%	1.60%	0.00%	0.37%	0.02%
Change (percentage)	+5.21%	-1.96%	+14.66%	-13.46%	-5.64%	-24.68%
Difference (percentage points)	+0.15%	-0.02%	+0.20%	-0.00%	-0.02%	-0.01%

	GLP-1 RA	Semaglutide	Tirzepatide	Liraglutide	Dulaglutide	Other
AOM						
June 2025	2.00%	0.68%	1.34%	0.01%	n/a	n/a
September 2025	2.13%	0.78%	1.39%	0.02%	n/a	n/a
Change (percentage)	+6.74%	+14.39%	+3.55%	+38.80%		
Difference (percentage points)	+0.13%	+0.10%	+0.05%	+0.00%		
Unknown						
June 2025	1.52%	0.80%	0.68%	0.05%	n/a	n/a
September 2025	1.55%	0.78%	0.73%	0.06%	n/a	n/a
Change (percentage)	+1.62%	-2.70%	+5.96%	+15.13%		
Difference (percentage points)	+0.02%	-0.02%	+0.04%	+0.01%		

- Overall prescribing rates (GLP-1 RA prescriptions per total prescriptions) in September 2025 are about the same relative to June 2025 (+4.60%).
- Month-over-month ADM prescribing increased from June to July and August to September 2025. ADM prescribing in September 2025 increased slightly compared to June 2025 (+5.21%).
- Among ADMs, tirzepatide is the most prescribed ADM medication.
- AOM prescribing increased slightly in September 2025 compared to June 2025 (+6.74%).
- Among AOMs, tirzepatide is the most prescribed AOM medication. AOM tirzepatide had small fluctuations between June and August 2025, before increasing in September 2025. AOM semaglutide increased from June to July but remained relatively stable through September.

Trends in First-Time Prescribing







	GLP-1 RA	Semaglutide	Tirzepatide	Liraglutide	Dulaglutide	Other
Overall						
June 2025	1.38%	0.60%	0.72%	0.01%	0.05%	0.00%
September 2025	1.20%	0.50%	0.65%	0.01%	0.04%	0.00%
Change (percentage)	-12.54%	-16.03%	-8.59%	-9.23%	-26.17%	-36.13%
Difference (percentage points)	-0.17%	-0.10%	-0.06%	-0.00%	-0.01%	-0.00%
ADM						
June 2025	0.47%	0.21%	0.21%	0.00%	0.05%	0.00%
September 2025	0.39%	0.16%	0.19%	0.00%	0.04%	0.00%
Change (percentage)	-16.76%	-23.03%	-7.89%	-35.82%	-26.17%	-36.13%
Difference (percentage points)	-0.08%	-0.05%	-0.02%	-0.00%	-0.01%	-0.00%
AOM						
June 2025	0.50%	0.16%	0.34%	0.00%	n/a	n/a
September 2025	0.46%	0.14%	0.31%	0.00%	n/a	n/a
Change (percentage)	-9.54%	-9.44%	-9.52%	-22.08%		
Difference (percentage points)	-0.05%	-0.01%	-0.03%	-0.00%		
Unknown						
June 2025	0.40%	0.23%	0.16%	0.01%	n/a	n/a
September 2025	0.36%	0.20%	0.15%	0.01%	n/a	n/a
Change (percentage)	-11.18%	-14.24%	-7.25%	-3.42%		
Difference (percentage points)	-0.04%	-0.03%	-0.01%	-0.00%		

- First-time prescribing rates (first-time GLP-1 RA prescriptions per total prescriptions) in September 2025 decreased compared to rates in June 2025 (-12.54%).
- First-time prescribing of ADMs decreased in September 2025, relative to June 2025 (-16.76%).
- First-time prescribing of AOMs decreased slightly in September 2025, relative to June 2025 (-9.54%).

Trends in Dispensing





	GLP-1 RA	Semaglutide	Tirzepatide	Liraglutide	Dulaglutide	Other
Overall						
March 2025	53.00%	51.20%	52.43%	59.54%	76.52%	68.25%
June 2025	53.72%	53.15%	52.32%	62.84%	77.53%	65.45%
Change (percentage)	+1.37%	+3.82%	-0.21%	+5.54%	+1.32%	-4.10%
Difference (percentage points)	+0.72%	+1.95%	-0.11%	+3.30%	+1.01%	-2.80%
ADM						
March 2025	71.43%	70.03%	71.70%	62.07%	76.52%	68.25%
June 2025	72.24%	70.36%	72.85%	71.43%	77.53%	65.45%
Change (percentage)	+1.13%	+0.47%	+1.60%	+15.08%	+1.32%	-4.10%
Difference (percentage points)	+0.81%	+0.33%	+1.14%	+9.36%	+1.01%	-2.80%
AOM						
March 2025	47.40%	47.34%	47.44%	47.44%	n/a	n/a

	GLP-1 RA	Semaglutide	Tirzepatide	Liraglutide	Dulaglutide	Other
June 2025	46.78%	48.59%	45.91%	58.33%	n/a	n/a
Change (percentage)	-1.31%	+2.65%	-3.21%	+22.97%		
Difference (percentage points)	-0.62%	+1.26%	-1.53%	+10.90%		
Unknown						
March 2025	37.54%	37.21%	36.57%	61.60%	n/a	n/a
June 2025	40.02%	40.48%	38.25%	63.37%	n/a	n/a
Change (percentage)	+6.60%	+8.78%	+4.60%	+2.88%		
Difference (percentage points)	+2.48%	+3.27%	+1.68%	+1.77%		

- During the full time period, 71.6% of GLP-1 RA prescriptions had a dispense within 60 days of their prescription (e.g., were initiated within 60 days).
- For patients first prescribed an ADM in June 2025, 72.2% filled a GLP-1 RA within 60 days. Initiation rates for ADM GLP-1 RA are about the same in June 2025, relative to March 2025 (+1.13%).
- For patients first prescribed an AOM in June 2025, 46.8% filled a GLP-1 RA within 60 days. Initiation rates for AOM GLP-1 RA are about the same in June 2025, relative to March 2025 (-1.31%).

About this report

This report provides recent trends in the prescribing and dispensing of glucagon-like peptide-1 receptor agonist (GLP-1 RAs)-based medications, including dual GLP-1 RA/gastric inhibitory polypeptide (GIP) over time, by medication, and by FDA-labeled use. We used near real-time, aggregated electronic health record (EHR) data from a collective of US healthcare systems to describe prescribing and dispensing of GLP-1 RA medications from January 2018 to September 2025.

Introduction

Obesity and type 2 diabetes mellitus (T2D) are closely linked epidemics with high prevalence and substantial negative impacts on health (CDC, 2020, Hales, 2020). Glucagon-like peptide-1 receptor agonist (GLP-1 RAs) -based medications, including dual GLP-1 RA/gastric inhibitory polypeptide (GIP), have been shown to improve glycemic control in patients with T2D and reduce weight in patients with and without T2D (Davies, 2015, Davies, 2021, Garvey, 2023, Jastreboff, 2022, Wilding, 2023, Yeh, 2023). GLP-1 RAs have also demonstrated cardiovascular benefit in patients with and without T2D (Lincoff, 2023, Ussher, 2023).

Interest in these medications has recently accelerated, largely for their weight-loss effects; however, limited empiric data exist on prescribing, dispensing, and patient characteristics. Access to and use of GLP-1 RA may be impacted by high cost, limited insurance coverage for patients without T2D, and medication shortages.

Methods

Data

We evaluated prescribing and dispensing of GLP-1 RAs between January 2018 and September 2025 using a subset of Truveta Data. Truveta provides access to continuously updated, linked, and de-identified electronic health record (EHR) from a collective of US health care systems that provide 18% of all daily clinical care in the US, including structured information on demographics, encounters, diagnoses, vital signs (e.g., weight, BMI, blood pressure), medication requests (prescriptions), medication administration, laboratory and diagnostic tests and results (e.g., HbA1c tests and values), and procedures. Updated EHR data are provided daily to Truveta by member health care systems. In addition to EHR data for care delivered within Truveta member health care systems, medication dispensing data are made available through linked third-party data. Medication dispense (via e-prescribing data) includes fills for prescriptions written both within and outside Truveta member health care systems, providing greater observability into patients' medication history. Medication dispense histories are updated at the time of the encounter and include fill dates, NDC or RxNorm codes, quantity dispensed, and days of medication supplied.

Population

We identified GLP-1 RA prescriptions (medication requests) and dispenses among adults using RxNorm and NDC codes for dulaglutide, exenatide, liraglutide, lixisenatide, semaglutide, and tirzepatide. Exenatide and lixisenatide were grouped as 'other' given small relative sizes. Brands were identified when possible using RxNorm and NDC codes. Brands labeled for treatment of T2D were classified as ADMs and brands labeled for treatment of overweight and obesity were classified as AOMs. When brand could not be established, the labeled use was classified as unknown.

Prescribing Analysis

Characteristics of patients ever prescribed a GLP-1 RA were summarized, including demographics, presence of T2D and/or overweight or obesity. Characteristics are provided by medication and by year of first prescription.

Overall and first-time prescribing rates of GLP-1 RA were summarized over time by medication and labeled use. The prescribing rate was calculated monthly as the number of patients with a GLP-1 RA prescription divided by the number of patients with any prescription in the month. Absolute differences and percentage changes in the rate of GLP-1 RA prescribing over the most recent 3-month period were summarized overall and by medication and labeled use.

Dispensing Analysis

We describe the proportion of GLP-1 RA prescriptions (overall and first-time) with a dispense occurring within 60 days. Dispensing analyses were restricted to prescriptions for which complete 60-day dispensing outcomes could be observed. Dispensing outcomes were considered observable if (1) a dispense was recorded in the 60 days following the prescription, and/or (2) an encounter took place after the 60-day period ended (at which time any dispenses would be observed). To allow sufficient follow-up, we report dispensing with a 90-day delay. Given shortages and expected substitutions at the pharmacy, we considered the dispense of any GLP-1 RA, which could differ from the prescribed GLP-1 RA.

We plot the proportion of prescriptions (overall and first-time) dispensed within 60 days over time, by medication and use. Differences in dispensing were expected between ADMs and AOMs given ADMs are typically covered by insurance, whereas insurance coverage for AOMs is limited. As such, we provide dispensing rates stratified by FDA labeled use. Further, we stratify dispensing by age 65+ vs. 18-64 as a proxy for Medicare coverage. Medicare never provides coverage for AOMs, whereas commercial insurers may.

Results

Overall population

The demographics of patients by first-prescribed medication are as follows:

Table 1: Patient Characteristics by First-Prescribed GLP-1 RA Medication.

	Semaglutide	Tirzepatide	Liraglutide	Dulaglutide	Other	Overall
N	1,298,442 (100.00%)	549,731 (100.00%)	155,797 (100.00%)	337,097 (100.00%)	42,224 (100.00%)	2,383,291 (100.00%)
Age Group						
18-44	343,513 (26.46%)	174,678 (31.78%)	42,223 (27.10%)	47,838 (14.19%)	4,895 (11.59%)	613,147 (25.73%)

	Semaglutide	Tirzepatide	Liraglutide	Dulaglutide	Other	Overall
45-64	623,515 (48.02%)	268,251 (48.80%)	77,157 (49.52%)	168,718 (50.05%)	19,952 (47.25%)	1,157,593 (48.57%)
65+	331,414 (25.52%)	106,802 (19.43%)	36,417 (23.37%)	120,541 (35.76%)	17,377 (41.15%)	612,551 (25.70%)
Sex						
Female	846,480 (65.19%)	371,209 (67.53%)	105,523 (67.73%)	181,869 (53.95%)	22,087 (52.31%)	1,527,168 (64.08%)
Male	451,962 (34.81%)	178,522 (32.47%)	50,274 (32.27%)	155,228 (46.05%)	20,137 (47.69%)	856,123 (35.92%)
Race						
White	926,803 (71.38%)	401,946 (73.12%)	112,815 (72.41%)	227,989 (67.63%)	30,813 (72.98%)	1,700,366 (71.35%)
Black or African American	177,846 (13.70%)	64,499 (11.73%)	21,610 (13.87%)	54,255 (16.09%)	5,241 (12.41%)	323,451 (13.57%)
Asian	34,095 (2.63%)	12,553 (2.28%)	2,898 (1.86%)	9,558 (2.84%)	1,006 (2.38%)	60,110 (2.52%)
Unknown	90,751 (6.99%)	43,400 (7.89%)	9,887 (6.35%)	25,190 (7.47%)	2,969 (7.03%)	172,197 (7.23%)
Native Hawaiian or Other Pacific Islander	4,749 (0.37%)	1,615 (0.29%)	690 (0.44%)	1,465 (0.43%)	177 (0.42%)	8,696 (0.36%)
American Indian or Alaska Native	9,330 (0.72%)	3,003 (0.55%)	1,707 (1.10%)	2,492 (0.74%)	371 (0.88%)	16,903 (0.71%)
Other Race	54,868 (4.23%)	22,715 (4.13%)	6,190 (3.97%)	16,148 (4.79%)	1,647 (3.90%)	101,568 (4.26%)
Ethnicity						
Hispanic or Latino	157,494 (12.13%)	65,668 (11.95%)	17,762 (11.40%)	45,843 (13.60%)	5,103 (12.09%)	291,870 (12.25%)
Not Hispanic or Latino	1,071,082 (82.49%)	453,036 (82.41%)	129,560 (83.16%)	270,616 (80.28%)	34,409 (81.49%)	1,958,703 (82.18%)
Unknown	69,866 (5.38%)	31,027 (5.64%)	8,475 (5.44%)	20,638 (6.12%)	2,712 (6.42%)	132,718 (5.57%)
Characteristics						
Type II Diabetes	545,966 (42.05%)	167,030 (30.38%)	72,120 (46.29%)	237,670 (70.50%)	30,473 (72.17%)	1,053,259 (44.19%)
Overweight or Obesity	908,423 (69.96%)	405,596 (73.78%)	96,583 (61.99%)	177,839 (52.76%)	21,226 (50.27%)	1,609,667 (67.54%)
Labeled Use						

	Semaglutide	Tirzepatide	Liraglutide	Dulaglutide	Other	Overall
ADM	570,360 (43.93%)	241,630 (43.95%)	53,049 (34.05%)	337,097 (100.00%)	42,224 (100.00%)	1,244,360 (52.21%)
AOM	262,484 (20.22%)	195,187 (35.51%)	31,861 (20.45%)	n/a	n/a	489,532 (20.54%)
Unknown	465,598 (35.86%)	112,914 (20.54%)	70,887 (45.50%)	n/a	n/a	649,399 (27.25%)
Year						
2018	3,785 (0.29%)	n/a	26,044 (16.72%)	22,471 (6.67%)	9,424 (22.32%)	61,724 (2.59%)
2019	17,736 (1.37%)	n/a	24,457 (15.70%)	29,278 (8.69%)	7,758 (18.37%)	79,229 (3.32%)
2020	31,153 (2.40%)	n/a	18,650 (11.97%)	31,923 (9.47%)	5,830 (13.81%)	87,556 (3.67%)
2021	71,575 (5.51%)	n/a	22,480 (14.43%)	48,289 (14.32%)	4,956 (11.74%)	147,6.300 (6.18%)
2022	168,394 (12.97%)	26,314 (4.79%)	26,073 (16.74%)	70,594 (20.94%)	5,074 (12.02%)	296,449 (12.44%)
2023	376,963 (29.03%)	73,911 (13.44%)	23,609 (15.15%)	72,754 (21.58%)	4,538 (10.75%)	551,775 (23.15%)
2024	391,584 (30.16%)	199,376 (36.27%)	10,048 (6.45%)	41,268 (12.24%)	3,245 (7.69%)	645,521 (27.09%)
2025	237,252 (18.27%)	250,130 (45.50%)	4,436 (2.85%)	20,520 (6.09%)	1,399 (3.31%)	513,737 (21.56%)
Comorbidity						
Asthma	185,468 (14.28%)	81,154 (14.76%)	22,701 (14.57%)	38,920 (11.55%)	4,314 (10.22%)	332,557 (13.95%)
CKD	150,896 (11.62%)	45,283 (8.24%)	19,480 (12.50%)	58,696 (17.41%)	7,285 (17.25%)	281,640 (11.82%)
COPD	64,097 (4.94%)	21,008 (3.82%)	8,896 (5.71%)	23,505 (6.97%)	2,962 (7.01%)	120,468 (5.05%)
Hyperlipidemia	671,182 (51.69%)	264,861 (48.18%)	68,700 (44.10%)	182,313 (54.08%)	22,779 (53.95%)	1,209,835 (50.76%)
Hypertension	685,602 (52.80%)	261,598 (47.59%)	78,439 (50.35%)	197,825 (58.68%)	25,015 (59.24%)	1,248,479 (52.38%)
Major Depression	158,207 (12.18%)	64,326 (11.70%)	19,904 (12.78%)	31,326 (9.29%)	3,608 (8.54%)	277,371 (11.64%)

Prescribing over time

Overall

We describe the monthly rate of prescriptions by medication and FDA labeled use over time:



First-time

We describe the monthly rate of first-time prescriptions by medication and FDA labeled use over time.



Characteristics of patients by year of first GLP-1 RA use are as follows:

Table 2: Patient Characteristics by Year of First GLP-1 RA Prescription.

	2018	2019	2020	2021	2022	2023	2024	2025
N	61,724 (100.0%)	79,229 (100.0%)	87,556 (100.0%)	147,300 (100.0%)	296,449 (100.0%)	551,775 (100.0%)	645,521 (100.0%)	513,737 (100.0%)
Age Group								
18-44	10,056 (16.3%)	13,002 (16.4%)	15,028 (17.2%)	28,701 (19.5%)	71,310 (24.1%)	146,068 (26.5%)	178,894 (27.7%)	150,088 (29.2%)
45-64	34,109 (55.3%)	42,261 (53.3%)	45,881 (52.4%)	75,022 (50.9%)	148,811 (50.2%)	273,511 (49.6%)	305,664 (47.4%)	232,334 (45.2%)
65+	17,559 (28.4%)	23,966 (30.2%)	26,647 (30.4%)	43,577 (29.6%)	76,328 (25.7%)	132,196 (24.0%)	160,963 (24.9%)	131,315 (25.6%)
Sex								
Female	34,385 (55.7%)	43,726 (55.2%)	48,067 (54.9%)	86,307 (58.6%)	189,129 (63.8%)	365,421 (66.2%)	425,538 (65.9%)	334,595 (65.1%)
Male	27,339	35,503	39,489	60,993	107,320	186,354	219,983	179,142

	(44.3%)	(44.8%)	(45.1%)	(41.4%)	(36.2%)	(33.8%)	(34.1%)	(34.9%)
Race								
White	47,079 (76.3%)	59,430 (75.0%)	64,293 (73.4%)	106,547 (72.3%)	213,606 (72.1%)	391,242 (70.9%)	457,039 (70.8%)	361,130 (70.3%)
Black or African American	7,944 (12.9%)	10,040 (12.7%)	11,642 (13.3%)	20,510 (13.9%)	42,225 (14.2%)	80,515 (14.6%)	85,117 (13.2%)	65,458 (12.7%)
Asian	1,276 (2.1%)	1,899 (2.4%)	2,317 (2.6%)	4,276 (2.9%)	7,416 (2.5%)	13,398 (2.4%)	16,283 (2.5%)	13,245 (2.6%)
Unknown	3,181 (5.2%)	4,402 (5.6%)	5,055 (5.8%)	8,254 (5.6%)	16,760 (5.7%)	36,397 (6.6%)	51,859 (8.0%)	46,289 (9.0%)
Native Hawaiian or Other Pacific Islander	233 (0.4%)	300 (0.4%)	373 (0.4%)	640 (0.4%)	1,169 (0.4%)	1,900 (0.3%)	2,311 (0.4%)	1,770 (0.3%)
American Indian or Alaska Native	453 (0.7%)	660 (0.8%)	691 (0.8%)	1,326 (0.9%)	2,332 (0.8%)	3,802 (0.7%)	4,441 (0.7%)	3,198 (0.6%)
Other Race	1,558 (2.5%)	2,498 (3.2%)	3,185 (3.6%)	5,747 (3.9%)	12,941 (4.4%)	24,521 (4.4%)	28,471 (4.4%)	22,647 (4.4%)
Ethnicity								
Hispanic or Latino	5,700 (9.2%)	8,085 (10.2%)	9,871 (11.3%)	18,057 (12.3%)	37,852 (12.8%)	67,675 (12.3%)	80,610 (12.5%)	64,020 (12.5%)
Not Hispanic or Latino	52,847 (85.6%)	66,809 (84.3%)	72,883 (83.2%)	121,765 (82.7%)	243,703 (82.2%)	455,061 (82.5%)	528,052 (81.8%)	417,583 (81.3%)
Unknown	3,177 (5.1%)	4,335 (5.5%)	4,802 (5.5%)	7,478 (5.1%)	14,894 (5.0%)	29,039 (5.3%)	36,859 (5.7%)	32,134 (6.3%)
Characteristics								
Type II Diabetes	43,626 (70.7%)	58,975 (74.4%)	63,246 (72.2%)	95,450 (64.8%)	153,141 (51.7%)	238,450 (43.2%)	235,065 (36.4%)	165,306 (32.2%)
Overweight or Obesity	40,093 (65.0%)	50,142 (63.3%)	52,855 (60.4%)	92,743 (63.0%)	186,321 (62.9%)	373,126 (67.6%)	448,353 (69.5%)	366,034 (71.2%)
Medication								
Semaglutide	3,785 (6.1%)	17,736 (22.4%)	31,153 (35.6%)	71,575 (48.6%)	168,394 (56.8%)	376,963 (68.3%)	391,584 (60.7%)	237,252 (46.2%)
Tirzepatide	<10	<10	<10	<10	26,314 (8.9%)	73,911 (13.4%)	199,376 (30.9%)	250,130 (48.7%)
Liraglutide	26,044 (42.2%)	24,457 (30.9%)	18,650 (21.3%)	22,480 (15.3%)	26,073 (8.8%)	23,609 (4.3%)	10,048 (1.6%)	4,436 (0.9%)
Dulaglutide	22,471 (36.4%)	29,278 (37.0%)	31,923 (36.5%)	48,289 (32.8%)	70,594 (23.8%)	72,754 (13.2%)	41,268 (6.4%)	20,520 (4.0%)

Other	9,424 (15.3%)	7,758 (9.8%)	5,830 (6.7%)	4,956 (3.4%)	5,074 (1.7%)	4,538 (0.8%)	3,245 (0.5%)	1,399 (0.3%)
Labeled Use								
ADM	38,085 (61.7%)	47,177 (59.5%)	60,755 (69.4%)	107,922 (73.3%)	209,140 (70.5%)	315,732 (57.2%)	284,131 (44.0%)	181,418 (35.3%)
AOM	1,829 (3.0%)	2,304 (2.9%)	3,425 (3.9%)	9,153 (6.2%)	22,381 (7.5%)	93,628 (17.0%)	179,564 (27.8%)	177,248 (34.5%)
Unknown	21,810 (35.3%)	29,748 (37.5%)	23,376 (26.7%)	30,225 (20.5%)	64,928 (21.9%)	142,415 (25.8%)	181,826 (28.2%)	155,071 (30.2%)
Comorbidity								
Asthma	6,922 (11.2%)	9,787 (12.4%)	10,958 (12.5%)	19,513 (13.2%)	39,548 (13.3%)	77,196 (14.0%)	92,605 (14.3%)	76,028 (14.8%)
CKD	9,701 (15.7%)	13,914 (17.6%)	16,032 (18.3%)	25,160 (17.1%)	38,615 (13.0%)	60,125 (10.9%)	65,712 (10.2%)	52,381 (10.2%)
COPD	3,819 (6.2%)	5,300 (6.7%)	6,015 (6.9%)	9,017 (6.1%)	14,920 (5.0%)	26,359 (4.8%)	30,513 (4.7%)	24,525 (4.8%)
Hyperlipidemia	35,295 (57.2%)	47,807 (60.3%)	51,202 (58.5%)	82,138 (55.8%)	150,103 (50.6%)	270,818 (49.1%)	315,826 (48.9%)	256,646 (50.0%)
Hypertension	37,220 (60.3%)	50,852 (64.2%)	54,135 (61.8%)	86,956 (59.0%)	158,046 (53.3%)	283,781 (51.4%)	322,981 (50.0%)	254,508 (49.5%)
Major Depression	6,342 (10.3%)	9,306 (11.7%)	10,531 (12.0%)	19,563 (13.3%)	37,456 (12.6%)	63,768 (11.6%)	72,078 (11.2%)	58,327 (11.4%)

60-day dispensing over time

We describe the proportion of patients with any GLP-1 RA prescriptions (first-time and repeat) in a given month who filled any GLP-1 RA in the 60 days following their prescription.



60-day initiation over time

We describe the proportion of patients first-prescribed a GLP-1 RA who filled any GLP-1 RA in the subsequent 60 days over time.



Patient characteristics are given in Table 3:

Table 3: Patient Characteristics by Dispense Status. Dispense status refers to presence of any GLP-1 RA dispense within 60 days of first GLP-1 RA prescription. Table contains the subset of patients with observable 60-day dispense outcomes.

	Dispensed in 60 Days	Not Dispensed in 60 Days	Overall
N	1,321,850 (100.00%)	908,232 (100.00%)	2,230,082 (100.00%)
Age Group			
18-44	299,600 (22.67%)	267,047 (29.40%)	566,647 (25.41%)
45-64	661,392 (50.04%)	427,915 (47.12%)	1,089,307 (48.85%)
65+	360,858 (27.30%)	213,270 (23.48%)	574,128 (25.74%)
Sex			
Female	817,843 (61.87%)	610,140 (67.18%)	1,427,983 (64.03%)
Male	504,007 (38.13%)	298,092 (32.82%)	802,099 (35.97%)
Race			
White	932,508 (70.55%)	661,491 (72.83%)	1,593,999 (71.48%)
Black or African American	182,195 (13.78%)	122,733 (13.51%)	304,928 (13.67%)
Asian	36,641 (2.77%)	20,252 (2.23%)	56,893 (2.55%)
Unknown	96,825 (7.32%)	58,751 (6.47%)	155,576 (6.98%)
Native Hawaiian or Other Pacific Islander	5,273 (0.40%)	2,989 (0.33%)	8,262 (0.37%)

	Dispensed in 60 Days	Not Dispensed in 60 Days	Overall
American Indian or Alaska Native	9,587 (0.73%)	6,350 (0.70%)	15,937 (0.71%)
Other Race	58,821 (4.45%)	35,666 (3.93%)	94,487 (4.24%)
Ethnicity			
Hispanic or Latino	165,648 (12.53%)	107,841 (11.87%)	273,489 (12.26%)
Not Hispanic or Latino	1,081,977 (81.85%)	754,633 (83.09%)	1,836,610 (82.36%)
Unknown	74,225 (5.62%)	45,758 (5.04%)	119,983 (5.38%)
Characteristics			
Type II Diabetes	700,027 (52.96%)	306,224 (33.72%)	1,006,251 (45.12%)
Overweight or Obesity	860,793 (65.12%)	675,073 (74.33%)	1,535,866 (68.87%)
Medication			
Semaglutide	693,612 (52.47%)	529,928 (58.35%)	1,223,540 (54.87%)
Tirzepatide	285,559 (21.60%)	207,701 (22.87%)	493,260 (22.12%)
Liraglutide	85,815 (6.49%)	64,430 (7.09%)	150,245 (6.74%)
Dulaglutide	231,716 (17.53%)	90,813 (10.00%)	322,529 (14.46%)
Other	25,148 (1.90%)	15,360 (1.69%)	40,508 (1.82%)
Labeled Use			
ADM	827,148 (62.58%)	351,146 (38.66%)	1,178,294 (52.84%)
AOM	209,805 (15.87%)	241,201 (26.56%)	451,006 (20.22%)
Unknown	284,897 (21.55%)	315,885 (34.78%)	600,782 (26.94%)
Year			
2018	33,276 (2.52%)	27,524 (3.03%)	60,800 (2.73%)
2019	47,467 (3.59%)	30,248 (3.33%)	77,715 (3.48%)
2020	52,874 (4.00%)	33,061 (3.64%)	85,935 (3.85%)
2021	91,784 (6.94%)	52,998 (5.84%)	144,782 (6.49%)
2022	188,432 (14.26%)	100,753 (11.09%)	289,185 (12.97%)
2023	333,239 (25.21%)	206,318 (22.72%)	539,557 (24.19%)
2024	350,468 (26.51%)	267,181 (29.42%)	617,649 (27.70%)
2025	224,310 (16.97%)	190,149 (20.94%)	414,459 (18.58%)
Comorbidity			
Asthma	178,334 (13.49%)	137,877 (15.18%)	316,211 (14.18%)

	Dispensed in 60 Days	Not Dispensed in 60 Days	Overall
CKD	172,824 (13.07%)	98,384 (10.83%)	271,208 (12.16%)
COPD	71,601 (5.42%)	43,571 (4.80%)	115,172 (5.16%)
Hyperlipidemia	690,561 (52.24%)	463,173 (51.00%)	1,153,734 (51.74%)
Hypertension	710,533 (53.75%)	474,144 (52.21%)	1,184,677 (53.12%)
Major Depression	145,186 (10.98%)	123,069 (13.55%)	268,255 (12.03%)

By Age

As a proxy for Medicare insurance, we segment initiation rate by populations 65+ versus 18-64.



Patient characteristics for patients aged 65+ are given in Table 4:

Table 4: Patient Characteristics by Dispense Status, Age 65+. Dispense status refers to presence of any GLP-1 RA dispense within 60 days of first GLP-1 RA prescription. Table contains the subset of patients with observable 60-day dispense outcomes.

	Dispensed in 60 Days	Not Dispensed in 60 Days	Overall
N	360,858 (100.00%)	213,270 (100.00%)	574,128 (100.00%)
Age Group			

	Dispensed in 60 Days	Not Dispensed in 60 Days	Overall
65+	360,858 (100.00%)	213,270 (100.00%)	574,128 (100.00%)
Sex			
Female	199,568 (55.30%)	122,057 (57.23%)	321,625 (56.02%)
Male	161,290 (44.70%)	91,213 (42.77%)	252,503 (43.98%)
Race			
White	278,706 (77.23%)	171,263 (80.30%)	449,969 (78.37%)
Black or African American	35,496 (9.84%)	20,061 (9.41%)	55,557 (9.68%)
Asian	8,337 (2.31%)	3,578 (1.68%)	11,915 (2.08%)
Unknown	23,608 (6.54%)	11,915 (5.59%)	35,523 (6.19%)
Native Hawaiian or Other Pacific Islander	795 (0.22%)	373 (0.17%)	1,168 (0.20%)
American Indian or Alaska Native	1,962 (0.54%)	1,027 (0.48%)	2,989 (0.52%)
Other Race	11,954 (3.31%)	5,053 (2.37%)	17,007 (2.96%)
Ethnicity			
Hispanic or Latino	29,009 (8.04%)	13,659 (6.40%)	42,668 (7.43%)
Not Hispanic or Latino	310,776 (86.12%)	188,228 (88.26%)	499,004 (86.92%)
Unknown	21,073 (5.84%)	11,383 (5.34%)	32,456 (5.65%)
Characteristics			
Type II Diabetes	240,224 (66.57%)	112,419 (52.71%)	352,643 (61.42%)
Overweight or Obesity	223,195 (61.85%)	143,370 (67.22%)	366,565 (63.85%)
Medication			
Semaglutide	191,828 (53.16%)	120,568 (56.53%)	312,396 (54.41%)
Tirzepatide	59,659 (16.53%)	36,997 (17.35%)	96,656 (16.84%)
Liraglutide	19,712 (5.46%)	14,695 (6.89%)	34,407 (5.99%)
Dulaglutide	79,343 (21.99%)	34,882 (16.36%)	114,225 (19.90%)
Other	10,316 (2.86%)	6,128 (2.87%)	16,444 (2.86%)
Labeled Use			
ADM	263,937 (73.14%)	109,684 (51.43%)	373,621 (65.08%)
AOM	19,120 (5.30%)	34,953 (16.39%)	54,073 (9.42%)
Unknown	77,801 (21.56%)	68,633 (32.18%)	146,434 (25.51%)
Year			
2018	9,174 (2.54%)	8,048 (3.77%)	17,222 (3.00%)
2019	13,757 (3.81%)	9,627 (4.51%)	23,384 (4.07%)
2020	15,594 (4.32%)	10,395 (4.87%)	25,989 (4.53%)

	Dispensed in 60 Days	Not Dispensed in 60 Days	Overall
2021	26,556 (7.36%)	16,036 (7.52%)	42,592 (7.42%)
2022	48,281 (13.38%)	25,311 (11.87%)	73,592 (12.82%)
2023	89,041 (24.67%)	39,597 (18.57%)	128,638 (22.41%)
2024	94,757 (26.26%)	58,926 (27.63%)	153,683 (26.77%)
2025	63,698 (17.65%)	45,330 (21.25%)	109,028 (18.99%)
Comorbidity			
Asthma	43,341 (12.01%)	27,611 (12.95%)	70,952 (12.36%)
CKD	102,555 (28.42%)	57,797 (27.10%)	160,352 (27.93%)
COPD	36,711 (10.17%)	22,581 (10.59%)	59,292 (10.33%)
Hyperlipidemia	239,712 (66.43%)	151,462 (71.02%)	391,174 (68.13%)
Hypertension	250,505 (69.42%)	156,767 (73.51%)	407,272 (70.94%)
Major Depression	38,930 (10.79%)	26,394 (12.38%)	65,324 (11.38%)

Patient characteristics for patients aged 18-65 are given in Table 5:

Table 5: Patient Characteristics by Dispense Status, Age 18-64. Dispense status refers to presence of any GLP-1 RA dispense within 60 days of first GLP-1 RA prescription. Table contains the subset of patients with observable 60-day dispense outcomes.

	Dispensed in 60 Days	Not Dispensed in 60 Days	Overall
N	960,992 (100.00%)	694,962 (100.00%)	1,655,954 (100.00%)
Age Group			
18-44	299,600 (31.18%)	267,047 (38.43%)	566,647 (34.22%)
45-64	661,392 (68.82%)	427,915 (61.57%)	1,089,307 (65.78%)
Sex			
Female	618,275 (64.34%)	488,083 (70.23%)	1,106,358 (66.81%)
Male	342,717 (35.66%)	206,879 (29.77%)	549,596 (33.19%)
Race			
White	653,802 (68.03%)	490,228 (70.54%)	1,144,030 (69.09%)
Black or African American	146,699 (15.27%)	102,672 (14.77%)	249,371 (15.06%)
Asian	28,304 (2.95%)	16,674 (2.40%)	44,978 (2.72%)
Unknown	73,217 (7.62%)	46,836 (6.74%)	120,053 (7.25%)

	Dispensed in 60 Days	Not Dispensed in 60 Days	Overall
Native Hawaiian or Other Pacific Islander	4,478 (0.47%)	2,616 (0.38%)	7,094 (0.43%)
American Indian or Alaska Native	7,625 (0.79%)	5,323 (0.77%)	12,948 (0.78%)
Other Race	46,867 (4.88%)	30,613 (4.40%)	77,480 (4.68%)
Ethnicity			
Hispanic or Latino	136,639 (14.22%)	94,182 (13.55%)	230,821 (13.94%)
Not Hispanic or Latino	771,201 (80.25%)	566,405 (81.50%)	1,337,606 (80.78%)
Unknown	53,152 (5.53%)	34,375 (4.95%)	87,527 (5.29%)
Characteristics			
Type II Diabetes	459,803 (47.85%)	193,805 (27.89%)	653,608 (39.47%)
Overweight or Obesity	637,598 (66.35%)	531,703 (76.51%)	1,169,301 (70.61%)
Medication			
Semaglutide	501,784 (52.22%)	409,360 (58.90%)	911,144 (55.02%)
Tirzepatide	225,900 (23.51%)	170,704 (24.56%)	396,604 (23.95%)
Liraglutide	66,103 (6.88%)	49,735 (7.16%)	115,838 (7.00%)
Dulaglutide	152,373 (15.86%)	55,931 (8.05%)	208,304 (12.58%)
Other	14,832 (1.54%)	9,232 (1.33%)	24,064 (1.45%)
Labeled Use			
ADM	563,211 (58.61%)	241,462 (34.74%)	804,673 (48.59%)
AOM	190,685 (19.84%)	206,248 (29.68%)	396,933 (23.97%)
Unknown	207,096 (21.55%)	247,252 (35.58%)	454,348 (27.44%)
Year			
2018	24,102 (2.51%)	19,476 (2.80%)	43,578 (2.63%)
2019	33,710 (3.51%)	20,621 (2.97%)	54,331 (3.28%)
2020	37,280 (3.88%)	22,666 (3.26%)	59,946 (3.62%)
2021	65,228 (6.79%)	36,962 (5.32%)	102,190 (6.17%)
2022	140,151 (14.58%)	75,442 (10.86%)	215,593 (13.02%)
2023	244,198 (25.41%)	166,721 (23.99%)	410,919 (24.81%)
2024	255,711 (26.61%)	208,255 (29.97%)	463,966 (28.02%)
2025	160,612 (16.71%)	144,819 (20.84%)	305,431 (18.44%)
Comorbidity			
Asthma	134,993 (14.05%)	110,266 (15.87%)	245,259 (14.81%)
CKD	70,269 (7.31%)	40,587 (5.84%)	110,856 (6.69%)

	Dispensed in 60 Days	Not Dispensed in 60 Days	Overall
COPD	34,890 (3.63%)	20,990 (3.02%)	55,880 (3.37%)
Hyperlipidemia	450,849 (46.91%)	311,711 (44.85%)	762,560 (46.05%)
Hypertension	460,028 (47.87%)	317,377 (45.67%)	777,405 (46.95%)
Major Depression	106,256 (11.06%)	96,675 (13.91%)	202,931 (12.25%)

Discussion and Conclusion

This analysis summarized GLP-1 RA prescribing trends and patient characteristics from January 2018 to September 2025. During this period 2,454,615 patients were prescribed a total of 12,203,009 total prescriptions. ADMs accounted for 75.3% of prescriptions, and AOMs accounted for 24.7%, among prescriptions where use was known. A larger proportion of ADMs, compared to AOMs, were dispensed within 60 days: 70.2% of first-time ADM prescriptions and 46.5% of first-time AOM prescriptions had a fill within 60 days.

Several limitations of our analysis should be noted. All data are preliminary and may change as additional data are obtained. These findings are consistent with data accessed October 10, 2025. Data presented in this analysis represent raw counts and/or rates, and post-stratification methods have not been conducted. In addition, cohorts with small counts may be suppressed during the de-identification process leading to the appearance of zero patients for a given time period. Given relatively large numbers of patients prescribed and dispensed GLP-1 RA, we do not expect substantial suppression in the most recent periods. The unknowns in this report either indicate the value was not included in the individual's electronic health record or that it was excluded from the data to protect an individual's identity as a part of Truveta's commitment to privacy (Truveta, 2024). Finally, this report is a description of prescribing trends and patient characteristics only. Results should not be interpreted as causal.

References

Truveta. (2024). Truveta's Approach to Patient Privacy.
https://resources.truveta.com/patient-privacy

Centers for disease control and prevention. "National diabetes statistics report". 2020.
https://www.cdc.gov/diabetes/data/statistics-report/index.html.

Davies, Melanie J., et al. “Efficacy of liraglutide for weight loss among patients with type 2 diabetes: the SCALE diabetes randomized clinical trial.” JAMA 314.7 (2015): 687-699.

Davies, Melanie, et al. “Semaglutide 2· 4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial.” The Lancet 397.10278 (2021): 971-984.

Hales, Craig M., et al. “Prevalence of obesity and severe obesity among adults: United States, 2017–2018. NCHS Data Brief, no 360.” National Center for Health Statistics 360 (2020): 1-7.

Han, Sabrina H., et al. “Public interest in the off-label use of glucagon-like peptide 1 agonists (Ozempic) for cosmetic weight loss: a google trends analysis.” Aesthetic Surgery Journal 44.1 (2024): 60-67.

Garvey, W. Timothy, et al. “Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial.” The Lancet (2023).

Jastreboff, Ania M., et al. “Tirzepatide once weekly for the treatment of obesity.” New England Journal of Medicine 387.3 (2022): 205-216.

Lincoff, A. Michael, et al. “Semaglutide and cardiovascular outcomes in obesity without diabetes.” New England Journal of Medicine 389.24 (2023): 2221-2232.

Ussher, John R., and Daniel J. Drucker. “Glucagon-like peptide 1 receptor agonists: cardiovascular benefits and mechanisms of action.” Nature Reviews Cardiology 20.7 (2023): 463-474.

Wilding, John PH, et al. “Once-weekly semaglutide in adults with overweight or obesity.” New England Journal of Medicine 384.11 (2021): 989-1002.

Whitley, Heather P., Jennifer M. Trujillo, and Joshua J. Neumiller. “Potential Strategies for Addressing GLP-1 and Dual GLP-1/GIP Receptor Agonist Shortages.” Clinical Diabetes (2023): cd230023.

Yeh, Tzu-Lin, et al. “Effect of glucagon-like peptide-1 receptor agonists on glycemic control, and weight reduction in adults: A multivariate meta-analysis.” PLOS One 18.1 (2023): e0278685.

Acknowledgements

The authors thank Dr. Ty Gluckman for his contributions and feedback on describing GLP-1 RA prescribing trends.